ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)
NCT ID: NCT00160680
Last Updated: 2023-08-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
62 participants
INTERVENTIONAL
2005-03-01
2006-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis
NCT00524836
Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis
NCT00439712
Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites
NCT00521131
Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics
NCT03365648
Safety Study of Levocetirizine and Fexofenadine
NCT01586091
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Continuous Treatment
5 mg of Levocetirizine (LCTZ) was taken orally once a day.
Levocetirizine
* Pharmaceutical form: Tablet
* Concentration: 5 mg
* Route of administration: Oral use
On Demand Treatment
5 mg of Levocetirizine (LCTZ) was taken whenever needed.
Levocetirizine
* Pharmaceutical form: Tablet
* Concentration: 5 mg
* Route of administration: Oral use
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levocetirizine
* Pharmaceutical form: Tablet
* Concentration: 5 mg
* Route of administration: Oral use
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive skin prick test (wheal \> 3 mm larger than the diluent control) or Radio Allergo Sorbent Assay (RAST) (\>= 3.5 IU/ml) to House Dust Mite (HDM) and Parietaria (less than 1 year).
* Minimum mean Total 4 Symptom Score (T4SS) of 6 over baseline period.
Exclusion Criteria
* Subjects suffering from non-allergic asthma
* Chronic use of inhaled steroids and/or long acting β2 agonists; and/or corticosteroids dependent asthma (severe asthma)
* Atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB S.A. - Pharma Sector
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Genova, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004-003858-26
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A00392
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.